Recently, Merck KGaA annnounced it was acquiring BioTechne for over $11 billion dollars. BioTechne's management has been strong - that's up from a $5B valuation about ten years ago. So the C-level team knew what it was doing.
But, if you look through a genomics lens, along the way the same BioTechne C-suite bought Exosome Dx for $325M (2018) and sold it for $15M (2025). Why was it so difficult to forecast the value of the Exosome business - by twenty-fold (5%)?
We discuss in a new white paper why the financials of the genomics industry can be so noisy, and often for reasons that will be missed by outsiders.
Our paper includs a humous appendix of real statements from genomic SEC documents. Like, 'We may get paid rarely, if ever."
Find the white paper in the cloud HERE.
